These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28411246)

  • 1. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
    Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
    J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
    Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
    Hagström E; James SK; Bertilsson M; Becker RC; Himmelmann A; Husted S; Katus HA; Steg PG; Storey RF; Siegbahn A; Wallentin L;
    Eur Heart J; 2016 Apr; 37(16):1325-33. PubMed ID: 26417057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
    Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
    Alfredsson J; Neely B; Neely ML; Bhatt DL; Goodman SG; Tricoci P; Mahaffey KW; Cornel JH; White HD; Fox KA; Prabhakaran D; Winters KJ; Armstrong PW; Ohman EM; Roe MT;
    Heart; 2017 Aug; 103(15):1168-1176. PubMed ID: 28381584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
    J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
    Jackson LR; Piccini JP; Cyr DD; Roe MT; Neely ML; Martinez F; Lüscher TF; Lopes RD; Winters KJ; White HD; Armstrong PW; Fox KA; Prabhakaran D; Bhatt DL; Magnus Ohman E; Corbalán R
    Clin Cardiol; 2016 Sep; 39(9):497-506. PubMed ID: 27468086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
    Ducrocq G; Schulte PJ; Becker RC; Cannon CP; Harrington RA; Held C; Himmelmann A; Lassila R; Storey RF; Sorbets E; Wallentin L; Steg PG
    EuroIntervention; 2015 Nov; 11(7):737-45. PubMed ID: 25254357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
    Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
    Cuisset T; Cayla G; Frere C; Quilici J; Poyet R; Gaborit B; Bali L; Morange PE; Alessi MC; Bonnet JL
    EuroIntervention; 2009 Aug; 5(3):325-9. PubMed ID: 19736156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
    Marquis-Gravel G; Neely ML; Valgimigli M; Costa F; Van Klaveren D; Altner R; Bhatt DL; Armstrong PW; Fox KAA; White HD; Ohman EM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006582. PubMed ID: 32862694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
    Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
    JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
    Smith JG; Wieloch M; Koul S; Braun OÖ; Lumsden J; Rydell E; Ohman J; Scherstén F; Svensson PJ; van der Pals J
    EuroIntervention; 2012 Oct; 8(6):672-8. PubMed ID: 23086784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Ducrocq G; Schulte PJ; Budaj A; Cornel JH; Held C; Himmelmann A; Husted S; Storey RF; Cannon CP; Becker RC; James SK; Katus HA; Lopes RD; Sorbets E; Wallentin L; Steg PG
    Am Heart J; 2017 Apr; 186():91-99. PubMed ID: 28454837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP; Husted S; Harrington RA; Scirica BM; Emanuelsson H; Peters G; Storey RF;
    J Am Coll Cardiol; 2007 Nov; 50(19):1844-51. PubMed ID: 17980250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.